Press Release

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio Bilthoven, the Netherlands, 19 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than…